Opendata, web and dolomites

CoALIVE TERMINATED

Coenzyme A – Launch of In Vivo Experiments

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CoALIVE project word cloud

Explore the words cloud of the CoALIVE project. It provides you a very rough idea of what is the project "CoALIVE" about.

cellular    market    bio    alternative    leaders    innovative    pkan    granting    orphan    obstacles    diverse    accelerate    expertise    untreatable    model    environment    implications    recruit    despite    rare    coa    ground    synthesis    acies    organism    medicines    expert    core    pantothenate    valuable    levels    approval    reaching    disease    designation    flies    contribution    ed    class    join    analytics    associate    medicinal    demonstrated    outstanding    treatment    breaking    therapeutics    underlying    phosphopantetheine    completion    patent    labour    affords    diabetes    models    innovation    strategy    alzheimer    facilities    agency    population    kinase    prior    recruitment    protection    phenotypic    coenzyme    successful    hindered    compound    commercial    assays    opportunity    national    metabolism    chemical    hire    proof    therapeutic    tircon    hence    pathologies    world    facility    laboratory    discovery    neurodegeneration    forms    evidenced    suffering    manipulate    treating    compounds    diseases    team    fruit    patients    metabolic    drug   

Project "CoALIVE" data sheet

The following table provides information about the project.

Coordinator
ACIES BIO BIOTEHNOLOSKE RAZISKAVE IN RAZVOJ DOO 

Organization address
address: TEHNOLOSKI PARK 21
city: LJUBLJANA
postcode: 1000
website: www.aciesbio.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Slovenia [SI]
 Total cost 74˙750 €
 EC max contribution 74˙750 € (100%)
 Programme 1. H2020-EU.2.3.2.2. (Enhancing the innovation capacity of SMEs)
 Code Call H2020-INNOSUP-02-2016
 Funding Scheme CSA
 Starting year 2017
 Duration (year-month-day) from 2017-09-29   to  2018-09-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ACIES BIO BIOTEHNOLOSKE RAZISKAVE IN RAZVOJ DOO SI (LJUBLJANA) coordinator 74˙750.00

Map

 Project objective

Acies Bio is looking to hire an expert on disease model development – particularly whole organism models in fruit flies – to join our drug discovery team developing 4-phosphopantetheine-related compounds for treating a range of Coenzyme A (CoA) metabolism related pathologies. Acies Bio’s lead compound is able to directly manipulate cellular CoA levels, which addresses the common underlying cause of this class of diseases. High therapeutic potential of this innovative treatment has been demonstrated for pantothenate-kinase-associated neurodegeneration (PKAN) and has resulted in the European Medicines Agency granting our lead compound orphan medicinal product designation. Application of this class of compounds to related diseases forms a core part of our Innovation Strategy, and could have far reaching implications in diverse areas such as numerous rare metabolic diseases, Alzheimer's disease and diabetes. This would not only make treatment available to a wider population of patients, suffering from currently untreatable conditions, but also open new opportunities for Acies Bio. Despite being world leaders in the field of CoA metabolism, as evidenced by our contribution to the TIRCON consortium, prior recruitment of relevant expertise has been hindered by obstacles within the national labour market. Hence, this call affords a valuable opportunity to recruit an Innovation Associate, to evaluate existing models in fruit flies, develop new disease models, implement novel phenotypic assays, and lead a dedicated facility. Acies Bio will provide outstanding coordination and support facilities, state-of-the-art chemical synthesis and analytics laboratory and a research-driven, commercial environment. Successful completion of this crucial step for proof-of-concept in alternative metabolic diseases, will accelerate patent protection and market approval of these ground-breaking therapeutics.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "COALIVE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "COALIVE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.3.2.2.)

ERBSN 4 H2020 (2020)

Eastern Romanian Business Support Network support for innovative SMEs

Read More  

SwissEENissme3.0 (2020)

“Swiss EEN Innovation Support actions for SMEs” in the frame of the European Innovation Council programme 2020-2021.

Read More  

InnosuppEastMed (2020)

Innovation Support Network East Mediterranean

Read More